Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 5/20 | 0.59 |
| ▸ | NOS1 | P29475 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | METAP2 | P50579 | 1/20 | 0.59 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.57 |
| ▸ | WNT3A | P56704 | 1/20 | 0.57 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | GSK3B | P49841 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29409358 | 1.00 | ROCK2 (0.59) | ROCK2NOS1MAPTROCK1KDM4E | |
| Bromide SCHEMBL17924434 | 0.98 | ROCK2 (0.57) | ROCK2NOS1MAPTROCK1KDM4E | |
| SCHEMBL16573980 | 0.84 | GSK3B (0.71) | ROCK2NOS1MAPTROCK1KDM4E | |
| SCHEMBL12354 | 0.83 | KDM4E (0.59) | NOS1MAPTKDM4EALDH1A1METAP2 | |
| SCHEMBL20060303 | 0.83 | KDM4E (0.59) | NOS1MAPTKDM4EALDH1A1METAP2 | |
| SCHEMBL13680578 | 0.80 | GSK3B (0.70) | ROCK2ROCK1CSNK2A1TRPA1GSK3B | |
| SCHEMBL29627018 | 0.79 | CDK2 (0.47) | ROCK2NOS1MAPTROCK1KDM4E | |
| SCHEMBL27537145 | 0.79 | GSK3B (0.64) | ROCK2NOS1MAPTROCK1KDM4E | |
| SCHEMBL14349688 | 0.79 | IDO1 (0.42) | MAPTKDM4EALDH1A1HPGDMETAP2 | |
| SCHEMBL15344157 | 0.76 | GSK3B (0.57) | ROCK2ROCK1METAP2CSNK2A1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1350 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017160361-A1 | POLYISOCYANURATE CATALYSTS FOR METAL PANELS AND SPRAY FOAMS | HUNTSMAN PETROCHEMICAL LLC (US) | 2017-09-21 | — | — | WO | claimed |
| EP-3057949-A1 | SECONDARY ALCOHOL QUINOLINYL MODULATORS OF RORyt | Janssen Pharmaceutica N.V. (BE) | 2016-08-24 | — | — | EP | claimed |
| WO-2015057206-A1 | SECONDARY ALCOHOL QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-23 | — | — | WO | claimed |
| EP-0904769-B1 | Keratin fibre dye compositions containing Indazole amine derivatives and dyeing method | OREAL (FR) | 2002-09-25 | — | — | EP | claimed |
| US-RE37781-E1 | VIRICIDES, PROTEASE INHIBITOR | DUPONT PHARMACEUTICALS COMPANY | 2002-07-02 | — | — | US | claimed |
| EP-0904769-A1 | Keratin fibre dye compositions containing Indazole amine derivatives and dyeing method | L'OREAL (FR) | 1999-03-31 | — | — | EP | claimed |
| US-5811422-A | USEFUL FOR TREATING VIRAL INFECTIONS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-09-22 | — | — | US | claimed |
| EP-0815108-A1 | CYCLIC UREA HIV PROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-01-07 | — | — | EP | claimed |
| US-5683999-A | Cyclic urea HIV protease inhibitors | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-11-04 | — | — | US | claimed |
| US-5610294-A | VIRAL TREATMENT | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-03-11 | — | — | US | claimed |
| WO-1997008150-A1 | SUBSTITUTED CYCLIC UREAS AND DERIVATIVES THEREOF USEFUL AS RETROVIRAL PROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-03-06 | — | — | WO | claimed |
| WO-1996029329-A1 | CYCLIC UREA HIV PROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-09-26 | — | — | WO | claimed |
| US-5559110-A | HIV ANTIVIRAL, GOOD SYSTEMIC ABSORPTION ADMINISTERED BY MOUTH | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-09-24 | — | — | US | claimed |
| US-4105656-A | PROCESS FOR PREPARING 3-N-MONOSUBSTITUTED AMINO-4-SUBSTITUTED-5-PYRAZOLONES | FUJI PHOTO FILM CO., LTD. (JP) | 1978-08-08 | — | — | US | claimed |
| US-20260060961-A1 | SUBSTITUTED HETEROCYCLES AS RAS INHIBITORS | JAZZ PHARMACEUTICALS IRELAND LTD (IE) | 2026-03-05 | — | — | US | disclosed |
| WO-2025242880-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE | MY-T BIO LIMITED (GB) | 2025-11-27 | — | — | WO | disclosed |
| US-20250353851-A1 | PURINES AND METHODS OF THEIR USE | KINETA INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-4585725-A | STORAGE STABILITY | FUJI PHOTO FILM CO., LTD. (JP) | 1986-04-29 | — | — | US | disclosed |
| EP-0137223-A2 | Photographic image-receiving element for silver salt diffusion transfer process | FUJI PHOTO FILM CO., LTD. (JP) | 1985-04-17 | — | — | EP | disclosed |
| US-4105656-A | PROCESS FOR PREPARING 3-N-MONOSUBSTITUTED AMINO-4-SUBSTITUTED-5-PYRAZOLONES | FUJI PHOTO FILM CO., LTD. (JP) | 1978-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060961-A1 | SUBSTITUTED HETEROCYCLES AS RAS INHIBITORS | KRAS, NRAS, HRAS | ROCK2 200/4885NOS1 3015/4885MAPT 4696/4885 |
| US-20250353851-A1 | PURINES AND METHODS OF THEIR USE | TDP1, TDP2, PIKFYVE | ROCK2 3281/4885NOS1 4048/4885MAPT 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.